Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-07-15 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2016年度股权激励计划股票授予验资报告
Audit Report / Information Classification · 95% confidence The document is titled as a '验资报告' which translates to 'Capital Verification Report' or 'Audit Report on Capital'. It is issued by a certified public accounting firm and relates to the verification of stock repurchase funds and shares for a specific date (2016-07-15). The content includes detailed audit procedures and confirmations regarding the company's stock repurchase and capital status. It is not a full annual report or interim financial report but a standalone audit report focusing on a specific capital verification task. The document length is 2259 characters, which is relatively short but contains substantive audit content, not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR).
2016-07-15 Chinese
北京德恒（昆明）律师事务所关于公司2016年度股权激励计划所涉限制性股票授予相关事宜的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and compliance of a company's 2016 equity incentive plan involving restricted stock grants. It references relevant laws, regulations, and company approvals related to the equity incentive plan. The document is not a financial report, earnings release, or regulatory filing about financial results. It is a standalone legal opinion on a specific corporate action (equity incentive plan). This fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and equity incentive plans, but not a full governance report or management announcement. The document length and content confirm it is not a brief announcement or a full annual report or audit report.
2016-07-15 Chinese
八届八次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on specific proposals related to the 2016 equity incentive plan, including restricted stock grants. The document includes voting counts and confirms compliance with company law and articles of association. It is not a full report, financial statement, or presentation but an official announcement of board/supervisory decisions. This fits best under Board/Management Information (MANG) as it relates to governance decisions and internal company resolutions rather than financial results or shareholder voting outcomes.
2016-07-15 Chinese
八届十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details decisions regarding the company's 2016 equity incentive plan, specifically the allocation of restricted stock and the determination of the grant date. The document includes voting results and references to relevant regulatory provisions. It is not a full financial report, audit, or earnings release, nor is it a presentation or legal proceeding update. It is a board decision announcement related to management and governance matters, specifically about stock incentives for executives and directors. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or announcement of a report publication.
2016-07-15 Chinese
独立董事关于2016年度股权激励计划所涉限制性股票授予的独立意见
Remuneration Information Classification · 95% confidence The document is an independent director's opinion on the 2016 annual equity incentive plan involving restricted stock grants. It discusses compliance with relevant laws, the number of shares granted, the eligibility of recipients, and the grant date. The document is a formal opinion related to a share-based incentive plan rather than a financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a regulatory announcement or a proxy solicitation. The content aligns best with a Remuneration Information filing, which covers compensation and equity incentive plans for executives and directors.
2016-07-15 Chinese
关于2016年度股权激励计划所涉限制性股票授予相关事宜的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the 2016 annual equity incentive plan involving the granting of restricted stocks by Kunming Pharmaceutical Group Co., Ltd. It details the decision procedures, approval status, grant date, number of shares granted, recipients, and legal and audit opinions related to the stock incentive plan. The document is a formal announcement of a corporate action related to stock incentives, including details on share repurchase and grant conditions. It is not a full financial report, audit report, or earnings release. It is also not a regulatory filing or a report publication announcement. The content fits best under a category related to capital or financing updates, as it involves share repurchase and equity incentive grants affecting the company's capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5404 characters) and detailed content support this classification with high confidence.
2016-07-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.